Previous 10 | Next 10 |
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA in...
2023-11-22 23:31:20 ET Summary ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of conviction relative to its main holdings. The f...
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35 th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York. Management wi...
2023-11-02 21:32:19 ET Codexis, Inc. (CDXS) Q3 2023 Earnings Conference Call November 02, 2023, 04:30 PM ET Company Participants Carrie McKim - Director of IR Stephen Dilly - President and CEO Kevin Norrett - Chief Operating Officer Sri Ryali - CFO Conf...
2023-11-02 17:10:02 ET More on Codexis Checking Out Codexis Codexis announces a San Carlos facility lease that could potentially save $30M Seeking Alpha’s Quant Rating on Codexis For further details see: Codexis reports mixed Q3 earnings; reaffirms...
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year Strong Financial Position Enables Projected Runway to Expected Positive Cash Flow Around End of 2026 Company to Host Virtual ECO Synth...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Codexis Inc. (CDXS) is expected to report $-0.32 for Q3 2023
2023-11-01 13:22:14 ET More on Codexis Checking Out Codexis Codexis announces a San Carlos facility lease that could potentially save $30M Seeking Alpha’s Quant Rating on Codexis Historical earnings data for Codexis Financial information for Co...
REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place...
News, Short Squeeze, Breakout and More Instantly...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...
2024-05-30 07:00:11 ET Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for CDXS on 2024-05-30 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, CDXS was trading at $3.19. CDXS currently trades -34.90% versus its...
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a f...